You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy
SBC: NEWVENTUREIQ LLC Topic: 102Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias
SBC: Path Biotech, LLC Topic: NIAPROJECT SUMMARY/ABSTRACT In response to National Institute on Aging's (NIA) strategic plan and PAS-19-317, we propose novel therapeuticsto treat Alzheimer disease and related dementias (ADRDs). We have developed novel combinations of three natural product compounds, which modulate complementary pathways in multiple types of CNS cells (i.e., neurons, microglia) associated with AD pathology. These c ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Minimally Invasive On Demand Electrical Nerve Block (OD-ENB) Device for Peripheral Pain
SBC: H-CUBED Topic: NIDAKnee Osteoarthritis (KOA) is a degenerative joint disease that leads to significant pain and functional disability affecting over 30% of older adults making it one of the most common and debilitating conditions related to aging. This disease results in a loss of mobility, reduced quality of life, and in ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Physics-informed Machine Learning approach for a selective, sensitive, and rapid sensor for detecting unsafe levels of carcinogenic/toxic VOCs
SBC: Prometheus Technologies, LLC Topic: NIEHSProject Summary Each year, between 340,000 and 900,000 premature deaths can be linked to air pollution caused by releasing Volatile Organic Compounds (VOCs), i.e., an estimated 1.8 billion tons of VOCs are emitted to the global environment each year. Also, some VOCs cause serious adverse health effects even at the trace level concentration, e.g., cancer, damage to the central nervous and immune sy ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring
SBC: Axioforce LLC Topic: NIBIBPROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing a new aspiration catheter solution for the treatment of large and medium vessel occlusions
SBC: ANEUVAS TECHNOLOGIES INC Topic: 104Project Summary/Abstract Stroke is the leading cause of serious long-term disability and accounts for 4.6 million disabled people in the United States. Stroke-related costs total over $46 billion in the United States each year.1 Of the nearly 800,000 Americans who have a stroke per year, 87% experience ischemic stroke1, of which 49%-86% are attributed to either large vessel occlusions (LVO) or med ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Biomarkers for Brain Resetting as an Assistive Tool in the Treatment of Status Epilepticus
SBC: Epifocus LLC Topic: 104The proposed phase-I STTR research is an interdisciplinary effort to develop more effective clinical management of Status Epilepticus (SE) in collaboration with one of the leading neurological institutes in the world, the Barrow Neurological Institute in Phoenix, Arizona. SE is a life-threatening neurological emergency that can occur without warning and is characterized by recurrent seizures witho ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Vitiligo topical treatment applying a potent, highly selective MC1R agonist
SBC: MC1R VENTURES LLC Topic: NIAMSPROJECT SUMMARY Vitiligo is the most common acquired hypopigmentary disorder that afflicts 0.5-2% of the world population, from all ethnicities and skin color. It is characterized by loss of melanocytes, which is often progressive, resulting in depigmented skin lesions. Vitiligo can be segmental (5-16% of all cases) or most commonly, non-segmental. It is a disease of young adults, as 25% of all no ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Adipose Targeted Gene Therapy for Lipodystrophy
SBC: ZVELT THERAPEUTICS INC. Topic: NIDDKPROJECT SUMMARY Lipodystrophy includes a heterogeneous group of disorders that are characterized by abnormal or degenerative conditions of the adipose tissue. This rare and often underdiagnosed condition can be partial/localized or generalized and is generally associated with metabolic disorders such as insulin resistance, diabetes, hyperglycemia, hyperlipidemia, and other severe conditions. Lipod ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.
SBC: Shift Pharmaceuticals Holdings, Inc. Topic: 106Abstract: The objective of this project is to perform the required (and previously approved) IND-enabling experimental work for E1v1.11, a novel drug candidate for Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is the leading genetic cause of infantile death worldwide, occurring in ~1:10,000 live births. The gene responsible for SMA is called survival motor neuron-1 (SM ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health